ArticleNature communications2025
A catalyst-free bioorthogonal reaction for malononitrile addition to azodicarboxylates.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Click chemistry-based drug delivery systems for targeted cancer therapy.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Developing bioorthogonal reactions that enable fundamental exploration of biological processes remains a key pursuit of chemical biology. We report here malononitrile addition to azodicarboxylate as a distinct class of catalyst-free bioorthogonal reactions. Our findings demonstrate that malononitriles react rapidly with azodicarboxylates in both organic and aqueous environments at ambient temperature, without requiring catalysts, bases, or additives. The facile modification of malononitriles facilitates their incorporation into biomolecules such as RNA and proteins. This malononitrile addition to azodicarboxylate reaction exhibits high robustness in complex biological systems, attributed to its distinct reactivity through a concerted transition state. Furthermore, we find that the malononitrile addition to azodicarboxylate reaction is compatible with other well-established bioorthogonal reactions (such as copper-catalyzed azide-alkyne cycloaddition and tetrazine ligation), enabling integration with click reactions for simultaneous site-specific labeling. These features position it as a valuable tool for various biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.